Article ID Journal Published Year Pages File Type
9005647 Clinical Therapeutics 2005 22 Pages PDF
Abstract
For patients with NSCLC in whom1026 more than 1 or 2 previous chemotherapeutic regimens have failed, erlotinib is an effective therapy with significant overall survival benefits. The use of erlotinib as first-line therapy in combination with platinum-based chemotherapeutic regimens, however, has failed to demonstrate efficacy in the treatment of NSCLC.
Related Topics
Health Sciences Medicine and Dentistry Medicine and Dentistry (General)
Authors
,